Vertex Pharmaceuticals Inc. - Company & Market Research Reports

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines. Founded in 1989 in Cambridge, MA, Vertex has research and development sites and commercial offices around the world in the United States, Canada, Europe and Australia. In May 2011, the U.S. Food and Drug Administration (FDA) approved Vertex’s first medicine, a treatment for hepatitis C. In 2012, Vertex received approval for our medicine for cystic fibrosis in the U.S., Europe and Canada. Vertex received Australian approval of our medicine for cystic fibrosis in 2013.


Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers - Product Thumbnail Image

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

  • Report
  • 155 Pages
From
Hepatitis Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Hepatitis Drug Development Pipeline Review, 2017

  • Report
  • 209 Pages
From
United Kingdom Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Pat - Product Thumbnail Image

United Kingdom Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Pat

  • Report
  • 366 Pages
From
The 2018-2023 World Outlook for Hepatitis C Treatments - Product Thumbnail Image

The 2018-2023 World Outlook for Hepatitis C Treatments

  • Report
  • 293 Pages
Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech - Product Thumbnail Image

Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech

  • Report
  • 130 Pages
From
Human Microbiome Applications in IVD and Other Healthcare - Product Thumbnail Image

Human Microbiome Applications in IVD and Other Healthcare

  • Report
  • 280 Pages
From
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide - Product Thumbnail Image

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

  • Report
  • 164 Pages
From
KOL Insight: Hepatitis C: the race for the first interferon-free regimen - Product Thumbnail Image

KOL Insight: Hepatitis C: the race for the first interferon-free regimen

  • Report
From
Global Markets and Manufacturing Technologies for Protein Drugs - Product Thumbnail Image

Global Markets and Manufacturing Technologies for Protein Drugs

  • Report
  • 176 Pages
From
Psoriasis Treatments 2012-2013 Patent Landscape - Product Thumbnail Image

Psoriasis Treatments 2012-2013 Patent Landscape

  • Report
  • 82 Pages
From
Cystic Fibrosis - Global Strategic Business Report - Product Thumbnail Image

Cystic Fibrosis - Global Strategic Business Report

  • Report
  • 252 Pages
From
Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030 - Product Thumbnail Image

Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030

  • Report
  • 443 Pages
From
Generic Drug Opportunity Assessment - Boceprevir (Victrelis) - Product Thumbnail Image

Generic Drug Opportunity Assessment - Boceprevir (Victrelis)

  • Report
From
Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease - Product Thumbnail Image

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

  • Report
  • 160 Pages
From
Pain Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Pain Drug Development Pipeline Review, 2017

  • Report
  • 229 Pages
From
Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment - Product Thumbnail Image

Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment

  • Report
  • 397 Pages
From
Global Gout Therapeutics Market 2016-2020 - Product Thumbnail Image

Global Gout Therapeutics Market 2016-2020

  • Report
  • 59 Pages
From
Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023 - Product Thumbnail Image

Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

  • Report
  • 87 Pages
From
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape - Product Thumbnail Image

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • Report
  • 120 Pages
From
Hepatitis C - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatitis C - Pipeline Review, H1 2018

  • Report
  • 431 Pages
From
Loading Indicator
adroll